AEterna Zentaris Profit Margin 2006-2021 | AEZS
Current and historical gross margin, operating margin and net profit margin for AEterna Zentaris (AEZS) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. AEterna Zentaris net profit margin as of June 30, 2021 is -161.21%.
|AEterna Zentaris Annual Profit Margins
|AEterna Zentaris Quarterly Profit Margins
||Medical - Biomedical and Genetics
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.